{
    "nctId": "NCT00128297",
    "briefTitle": "Pamidronate Administration in Breast Cancer Patients With Bone Metastases",
    "officialTitle": "Randomized, Multicentric Phase IV Clinical Trial for the Administration of Pamidronate in Breast Cancer Patients With Bone Metastases",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Neoplasm Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 152,
    "primaryOutcomeMeasure": "Pamidronate efficacy to prevent first skeletal event: time until the appearance of the first skeletal event",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent.\n* Up to two previous or current hormone therapy treatments for metastatic breast cancer are allowed.\n* Normal or borderline renal function (serum creatinine \\< 1.5 x upper normal limit \\[UNL\\]).\n* Normal calcium levels in serum, or slightly non-symptomatic high levels (\\< 1.25 x UNL).\n* Performance status 0, I or II in World Health Organization (WHO) scale.\n\nExclusion Criteria:\n\n* Treatment with bisphosphonates in the 30 previous days, or any time if the indication was treatment of metastatic bone lesions.\n* Treatment with bisphosphonates is only allowed if the indication is hypercalcaemia.\n* Metastases in central nervous system (CNS).\n* Hypersensitivity to bisphosphonates or other components of the formula.\n* Pregnant or lactating women.\n* Previous or current treatment with a second chemotherapy line or a third hormone therapy line for metastatic disease.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}